Search
Triazolam
go.drugbank.com/drugs/DB00897ApprovedInvestigationalWithdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnA competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. Having been ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ONDANSETRON 4 LINGUAL 1A P, ONDANSETRON 8 LINGUAL 1A PQuinidine
go.drugbank.com/drugs/DB00908ApprovedQuinidine is a D-isomer of quinine present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. Quinidine is considered the first an...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalZonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium c...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTinidazole
go.drugbank.com/drugs/DB00911ApprovedInvestigationalA nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRepaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalRepaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approvedBuprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addi...
Categories: Cytochrome P-450 CYP2C18 Substrates, P-glycoprotein inhibitorsProducts: TRANSTEC PRO 35MCG/H20MG/P, TRANSTEC PRO 70MCG/H40MG/PCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepre...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesOxymetazoline
go.drugbank.com/drugs/DB00935ApprovedInvestigationalOxymetazoline is an imidazole derivative and a potent, direct-acting alpha (α)-adrenergic agonist with affinity to both α1- and α2-adrenoceptors. Oxymetazoline is available in various formulations with a wide variety of clinical implicat...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesFexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigationalFexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H1 receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain...
Categories: P-glycoprotein substrates